Navigation Links
Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
Date:5/13/2011

PRINCETON, N.J., May 13, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2011.

Soligenix's revenues for the first quarter of 2011 were approximately $808,000 as compared to $336,000 for the first quarter of 2010. The increased revenues were primarily a result of increases in National Institutes of Health (NIH) grant revenues as the Company increased research efforts under its thermostable vaccine development program and under its FDA Orphan Products grant for the confirmatory Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host disease (GI GVHD).

Soligenix's net loss for the first quarter of 2011 was approximately $1,720,000, or $(0.01) per share, as compared to $2,136,000, or $(0.01) per share for the first quarter of 2010.

Research and development expenses for the first quarter of 2011 were approximately $1,256,000, compared to $1,598,000 for the first quarter of 2010. General and administrative expenses for the first quarter of 2011 were approximately $564,000, compared to approximately $538,000 for the first quarter of 2010.

"While the first quarter of 2011 was quite eventful for us, our primary focus continues to be the conduct of our confirmatory Phase 3 orBec® clinical trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We remain committed to our goal of having orBec® become the first FDA-approved therapy to treat GI GVHD, an area of unmet medical need associated with high morbidity and mortality rates. On the biodefense and vaccine side of our business, we received Orphan Drug designation for RiVax™ and also executed a license on new technology that will potentially enable us to develop vaccines that are stable at elevated temperatures. We also achieved positive results of SGX202 in a canine model of rad
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
2. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
3. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
4. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
5. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
6. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
9. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
10. Soligenix Reports Third Quarter 2009 Financial Results
11. Soligenix to Present at 8th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Reportlinker.com announces that a new market research report is ... - technologies, markets and companies ... Up-to-date on-stop information on gene therapy with 72 tables and ... - 700 selected references from the literature ...
... announces that a new market research report is ... applications, markets and companies ... creation and utilization of materials, devices, and systems ... scale (a nanometer is one billionth of a ...
... strip with two surfaces but only one side, has been ... German mathematician August Mbius. As artist M.C. Escher so vividly ... traverse the "inside" and "outside" surfaces of a Mbius strip ... searching for an example of Mbius symmetry in natural materials ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Reportlinker Adds Nanobiotechnologies- applications, markets and companies 2Reportlinker Adds Nanobiotechnologies- applications, markets and companies 3Reportlinker Adds Nanobiotechnologies- applications, markets and companies 4Reportlinker Adds Nanobiotechnologies- applications, markets and companies 5Reportlinker Adds Nanobiotechnologies- applications, markets and companies 6Reportlinker Adds Nanobiotechnologies- applications, markets and companies 7Reportlinker Adds Nanobiotechnologies- applications, markets and companies 8Reportlinker Adds Nanobiotechnologies- applications, markets and companies 9Reportlinker Adds Nanobiotechnologies- applications, markets and companies 10Reportlinker Adds Nanobiotechnologies- applications, markets and companies 11Reportlinker Adds Nanobiotechnologies- applications, markets and companies 12Reportlinker Adds Nanobiotechnologies- applications, markets and companies 13Reportlinker Adds Nanobiotechnologies- applications, markets and companies 14Reportlinker Adds Nanobiotechnologies- applications, markets and companies 15Reportlinker Adds Nanobiotechnologies- applications, markets and companies 16
(Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
(Date:7/9/2014)... season upon us, many backyard cooks are turning to ... dogs. But low fat can sometimes mean low satisfaction. ... texture problem in low-fat wieners that are made with ... published in ACS, Journal of Agricultural and Food ... that hot-dog consumers have come to expect just the ...
(Date:7/9/2014)... re-examination of a sparrow-sized fossil from China challenges the ... dinosaurs that gained the ability to fly. The birdlike ... but much rather the remains of a tiny tree-climbing ... of the Dinosaur Museum in Blanding, Utah, and Alan ... appears in Springer,s Journal of Ornithology . , ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... always been what they are today, particularly for omnivores. ... tigers and other big cats as examples. Other mammals ... on a diet of leaves, shoots, fruits and bark. ... addition to meat, the situation wasn,t always that way, finds ...
... , This release is available in ... the US and Europe harbour more plant species than ... closer related to each other and often share similar ... environmental impacts than rural ecosystems. This is concluded by ...
... 18/04/12 - Technology has transformed the way humans interact with ... ideas that will drive growth in marine and maritime sectors ... policy will gather at the 3rd Marine Board Forum in ... Board has convened this flagship event on the understanding that ...
Cached Biology News:Scientists trace evolutionary history of what mammals eat 2Live fast, die young 2New technologies for a blue future 2
Eagle's Ham's amino acids; EHAA...
... IRsolution software provides quick and easy operation ... with Windows-based control. The software is ... FDA 21 CFR Part 11 regulations, and ... measurement. IRsolutions versatility enables use in ...
... introduce random mutations to the gene supplied by ... into a vector of choice to obtain a ... can be set to a desired value within ... 106-108. Mutations can be restricted to a ...
... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
Biology Products: